insights_auto
Why is FARN down 3,92%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
35,07 GBX
arrow_downward
-3,92%(-1,43) 1D
13-окт., 16:30:00 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
38,00 GBX
High
38,00 GBX
Low
35,07 GBX
Mkt. cap
71,06 млн
Avg. vol.
42,86 миң
Volume
27,01 миң
52-wk high
193,58 GBX
52-wk low
34,00 GBX
EPS
-0,10 GBX
Shares outstanding
31,03 млн
No. of employees
36
Open
38,00 GBX
High
38,00 GBX
Low
35,07 GBX
Mkt. cap
71,06 млн
Avg. vol.
42,86 миң
Volume
27,01 миң
52-wk high
193,58 GBX
52-wk low
34,00 GBX
EPS
-0,10 GBX
Shares outstanding
31,03 млн
No. of employees
36
News stories
From web sources and news partners
Simply Wall Street
·
3 мүнөт мурун
Cisco Systems (CSCO) Rolls Out 400G USFP Standard For AI Networking
Benzinga
·
51 мүнөт мурун
VERAXA Biotech (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at Worl
Stock Titan
·
1 саат мурун
Nasdaq files to remove Bone Biologics (Nasdaq: BBLG) warrants from listing and/or registration.
Yahoo Finance
·
32 мүнөт мурун
XRP Fell 8% in the Week It Got a Nasdaq Listing, a Dubai Bank Deal and an ETF Inflow. Why Did None of It Count?
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy